The purpose of this research is to determine how well different doses of SRSD107 work in preventing blood clots compared to enoxaparin in people having knee replacement surgery. During the study, participants will receive either SRSD107 or enoxaparin as injections under the skin. Some participants will also receive sodium chloride solution injections.

The study will monitor participants before their surgery and continue following them for several months afterward. Doctors will check for any signs of blood clots and assess if the medications are working safely. They will use special imaging tests to look for blood clots in the leg that received surgery. The study will also track any bleeding or other health issues that might occur during the treatment period.

The research focuses on frail older patients over 70 years of age who are taking DOACs. Frailty is a condition characterized by reduced strength, endurance, and physiological function that increases vulnerability to health problems. The study will measure the levels of DOACs in participants’ blood and make adjustments to their medication dosage when necessary.

The researchers will track whether this strategy reduces complications such as bleeding events or thromboembolic events (blood clots that can travel through the bloodstream). Ischemic stroke (when a blood vessel supplying blood to the brain is blocked), transient ischemic accident (TIA) (a temporary period of symptoms similar to a stroke), and peripheral thromboembolism (blood clots in vessels away from the heart and brain) will be monitored as part of the study.

The purpose of the study is to evaluate whether Abelacimab is as effective as Apixaban in preventing the recurrence of VTE in patients with cancer over a period of six months. If Abelacimab proves to be at least as effective, the study will further assess if it might be even better. Participants in the study will receive either Abelacimab or Apixaban and will be monitored for any recurrence of VTE and any bleeding events during the six-month period.

This trial is designed to provide valuable information on the effectiveness and safety of these treatments for patients with cancer-related VTE. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered, but the evaluation of the results is blinded to ensure unbiased assessment. The trial aims to help improve treatment options for patients dealing with this serious condition.

Participants in the study will receive either Abelacimab or Fragmin® for a period of six months. The study is designed to monitor the recurrence of VTE and any bleeding events during this time. Abelacimab is administered through a method called subcutaneous use, which means it is injected under the skin. Similarly, Fragmin® is also given through subcutaneous injection. The study aims to determine if Abelacimab can prevent VTE recurrence as effectively as Fragmin® and, if successful, to see if it might be even better.

Throughout the study, participants will be closely monitored to track any occurrences of VTE and to ensure their safety. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. However, the evaluation of the study’s outcomes is blinded, meaning that the people assessing the results do not know which treatment the participants received, to ensure unbiased results. The study is expected to continue until 2025, providing valuable information on the effectiveness of Abelacimab in treating VTE in patients with GI or GU cancer.

The trial will involve several medications, including Enoxaparin Sodium, Dabigatran, Nadroparin Calcium, Apixaban, Dalteparin Sodium, Rivaroxaban, Andexanet Alfa, and a combination product containing Human Coagulation Factors. These medications are known as anticoagulants, which help prevent blood clots. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Participants in the study will be monitored for three months after their surgery to track the occurrence of VTE and any major bleeding events. The study will also look at other health outcomes, such as heart attacks, strokes, and infections related to the joint replacement. The goal is to find the best way to prevent blood clots while ensuring patient safety during and after surgery.

Participants in the study will be randomly assigned to receive either apixaban or no anticoagulant treatment. Both groups will receive standard care, which includes mechanical methods to prevent blood clots, such as compression stockings. The study will monitor the occurrence of blood clots and any bleeding complications over a period of 90 days after surgery. The goal is to determine if apixaban provides a net benefit in preventing blood clots without causing significant bleeding.

The trial will also assess the safety of apixaban by tracking any major bleeding events, which could include a significant drop in hemoglobin levels, the need for blood transfusions, or bleeding that requires additional medical intervention. The study will help to clarify whether using apixaban is a safe and effective option for patients undergoing these types of surgeries.

The purpose of the study is to evaluate whether treatment with these blood thinners affects the risk of bleeding that requires medical attention or leads to death within 30 days of starting the treatment. Participants in the study will receive either TINZAPARIN or DALTEPARIN through a subcutaneous injection, which means the medication is injected under the skin. The study will monitor patients over a period of time to observe any major bleeding events or other health outcomes.

Throughout the study, researchers will track various health indicators, such as the need for blood transfusions, the occurrence of pulmonary embolism (a blockage in the lung’s blood vessels), and any signs of heparin-induced thrombocytopenia (a condition where the blood has a lower than normal number of platelets). The study will also look at overall survival rates and the length of hospital stays. This information will help determine the safety and effectiveness of these blood thinners in treating patients with venous thromboembolism.

The purpose of the study is to compare the safety of these two medications in treating VTE. Participants in the study will be randomly assigned to receive either Rivaroxaban or Apixaban, or a placebo, and will take the medication orally for a period of up to three months. The study will monitor the occurrence of bleeding events, which are a potential side effect of these medications, to determine which treatment is safer.

Throughout the study, researchers will track various outcomes, including the rate of bleeding events, any recurrence of VTE, and overall survival rates. The study aims to provide valuable information on the safety and effectiveness of Rivaroxaban and Apixaban in treating acute venous thromboembolism, helping to guide future treatment decisions for this condition.